Straits Times Index
3,306.02 +6.02 (+0.18%) Nikkei
38,596.47 -36.55 (-0.09%) Hang Seng
18,028.52 -306.80 (-1.67%) FTSE 100
8,237.72 -34.74 (-0.42%) Bitcoin USD
64,361.05 +142.11 (+0.22%) CMC Crypto 200
1,350.78 -9.54 (-0.70%)
ImmunoPrecise Antibodies Ltd. (TQB.F)
| Previous close | 0.8800 |
| Open | 0.8500 |
| Bid | 0.9050 x N/A |
| Ask | 0.9950 x N/A |
| Day's range | 0.8500 - 0.8500 |
| 52-week range | 0.8500 - 2.8400 |
| Volume | |
| Avg. volume | 99 |
| Market cap | 24.826M |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3900 |
| Earnings date | 05 Jul 2024 - 09 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
VICTORIA, British Columbia, June 12, 2024--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("ImmunoPrecise" or "IPA" or the "Company"), a leader in AI-driven biotherapeutic research and technology, today announces that its subsidiary, BioStrand, has been honored with the prestigious 2024 Impact Award, sponsored by InterSystems. This recognition highlights BioStrand’s groundbreaking work in biotherapeutic research, which has made a significant impact and set a new standard for innovation in the indus
Business WireBioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
VICTORIA, British Columbia, June 10, 2024--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("ImmunoPrecise" or "IPA" or the "Company"), a leader in AI-driven biotherapeutic research and technology, today announces the commercial release of LENSai API, hereafter referred to as the ‘software’, by its subsidiary, BioStrand. This advanced AI-driven software solution is available immediately.
Business WireIPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
VICTORIA, British Columbia, June 04, 2024--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that its Belgian subsidiary, BioStrand, is leveraging their patented Foundation AI Model, LENSai, by applying advanced Large Language Models (LLM) to capture real world data from Electronic Health Records (EHR). LENSai significantly enhances the analysis and integration of EHR data,
